We rank companies based on fund manager, research analyst and news sentiment
XENE stock icon

Xenon Pharmaceuticals
XENE

$39.88
1.07%
 

About: Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.

Employees: 259

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 11 analysts
0
News positive %
of 3 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

105% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 22

65% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 51

58% more capital invested

Capital invested by funds: $2.09B [Q3] → $3.32B (+$1.22B) [Q4]

40% more funds holding in top 10

Funds holding in top 10: 10 [Q3] → 14 (+4) [Q4]

23% more call options, than puts

Call options by funds: $34.2M | Put options by funds: $27.9M

13% more funds holding

Funds holding: 178 [Q3] → 201 (+23) [Q4]

1.89% more ownership

Funds ownership: 95.55% [Q3] → 97.44% (+1.89%) [Q4]

Research analyst outlook

11 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$46
15%
upside
Avg. target
$58
46%
upside
High target
$65
63%
upside

11 analyst ratings

11 positive
100%
neutral
0%
negative
0%
Needham
Serge Belanger
55%upside
$62
Buy
Reiterated
12 Apr 2024
Cantor Fitzgerald
Josh Schimmer
63%upside
$65
Overweight
Reiterated
10 Apr 2024
RBC Capital
Brian Abrahams
38%upside
$55
Outperform
Maintained
1 Mar 2024
Wedbush
Laura Chico
28%upside
$51
Outperform
Maintained
1 Mar 2024
Needham
Serge Belanger
55%upside
$62
Buy
Maintained
1 Mar 2024

Financial journalist opinion

Based on 3 articles about XENE published over the past 30 days